Crizotinib is a tyrosine kinase inhibitor (TKI) that was approved by the FDA in 2011 to treat ALK-mutated locally advanced or metastatic NSCLC after clinical trials showed good objective response rates and increased progression-free survival [4]. Here, ALK is linked to non-small cell lung carcinoma.